antipyschotic medications

Question 1

chlorpromazine

Answer 1

atypical
1st antipyschotic, but no longer first line
aliphatic

Question 2

promethazine

Answer 2

atypical
aliphatic
used for H1 antagonist properties
used for N/V

Question 3

thioridazine

Answer 3

atypical
sedation, hypotension, anticholinergic
piperadine

Question 4

fluphenazine

Answer 4

strong D2 blocker
EPS
piperazine

Question 5

prochlorperazine

Answer 5

antiemetic
piperazine

Question 6

perphenazine

Answer 6

CATIE study: had perphenazine and antichlinergics vs several newer agents

Question 7

thiothixene

Answer 7

modest EPS

Question 8

molindone

Answer 8

moderate EPS
atypical

Question 9

pimozide (ORAP)

Answer 9

tourettes

Question 10

clozapine

Answer 10

1st atypical
most effective
agrunulocytosis, anticholinergic, antihistinime, risk of diabetes

Question 11

olanzapine

Answer 11

1A2
weight gain
risk of diaebetes
less likely N/V or movement disorders

Question 12

loxapine

Answer 12

metabolite is amoxipine
inhibits NET –> antidepressant

Question 13

quetiapine

Answer 13

5HT2 + D2
low EPS
risk diabetes
hyptotension (a1), sedation (H1)

Question 14

risperidone

Answer 14

2D6, minor 3A4
EPS, hyperprolactinemia
weight gain
some sedation

Question 15

paliperidone

Answer 15

renally eliminated - dose adjustments in renal impairment
QTc prolongation

Question 16

iloperidone

Answer 16

2D6
QTc prolongation
high risk orthostasis and syncope
very potent at a1 receptor

Question 17

ziprasidone

Answer 17

5HT2A, D2, A1 affinity
contracindication: prolongs QT
3A4
take with food

Question 18

lurasidone

Answer 18

5HT2A + D2
less weight gain and metabollic effects than olanzapine

Question 19

pimavanserin

Answer 19

inverse agonist 5HT2a
used for parkinsons pyschosis
3A4

Question 20

aripiprazole

Answer 20

high affinity for 5HT2a and D2
partial agonist at 5HT2a used for depression
moderate affinity for D4, a, and histamine receptors
sides: weight gain, low risk D2 sides

Question 21

brexpiprazole

Answer 21

D2/D3 partial agonists
supposedly less akathisia vs aripiprazole

Question 22

cariprazine

Answer 22

D2/D3 partial agonist with greater affinity for D3
weak partial agonist at 5HT1a

Question 23

lumateperone

Answer 23

partial agonist presynaptic receptors/ antagonist at postsynatpic receptor
low risk metabollic side effects, EPS, akathisia
3A4

Question 24

aripiprazole, brexipiprazole, cariprazine

Answer 24

partial agonists D2
5HT2A antagonist
2D6 and 3A4 substrates
moderate akathisia
low-moderate weight gain

Question 25

which drugs are the ‘pines’

Answer 25

asenapine
clozapine
olanzapine
quetiapine

Question 26

asenapine risks

Answer 26

1A2 substrate
QTc prolongation
sublingual and patch formulations

Question 27

clozapine

Answer 27

boxed warning: neutropenia, orthostasis, breafycardia
sides: sedation, weight gain, constipation
QTc prolongation

Question 28

olanzapine risks

Answer 28

1A2 substrate
significant weight gain
metabollic syndrome
dress warning

Question 29

quetiapine risks

Answer 29

3A4 substrate
QTc prolongation
weight gain and sedation
boxed warning for suicidal ideation
REMS monitoring weekly for 6 months then bi weekly for 6 months then q4 weeks

Question 30

samidorphan

Answer 30

opioid antagonist at mu opioid receptor
used in combination with olanzapine

Question 31

the dones

Answer 31

D2 and 5HT2A antagonist
iloperidone, lurasidone, ziprasidone, risperidone, paliperidone

Question 32

haloperidol

Answer 32

EPS
given Q4week

Question 33

What are VMAT inhibitors?

Answer 33

valbenazine, deutetrabenazine, valbenazine

Question 34

valbenazine

Answer 34

2D6/3A4 substrate
QTc prolongation